KRAS169 Q61H , and KRAS188 G12D cDNAs were cloned into the pRK-172 vector using NdeI and BamHI restriction sites. Genes were placed in-frame with an N-terminal 6 x his-tag and the TEV protease recognition site. KRAS188 WT and KRAS188 G12V constructs were generated using QuikChange Site-Directed Mutagenesis kit (Agilent Technologies, USA) using pRK-172-KRAS188 G12D vector as a template. Plasmids containing pRK-172-6xHis-TEV-KRAS169 Q61H , KRAS188 G12D , KRAS188 WT or KRAS188 G12V sequences were transformed individually into B834(DE3)pLysS cells, which were grown in 25 ml LB medium with 50 μg/ml Carbenicillin and 34 μg/ml Chloramphenicol for 16 hours, before adding to 1L LB medium containing the same antibiotics. Protein expression was induced when cells reached an OD600 of 0.6 by addition of 1-thio-β-D-galactopyranoside (IPTG) to a final concentration of 0.5 mM followed by overnight incubation at 16°C. Bacteria were harvested by centrifugation (5180g, 30 mins, 4 °C ) resuspended in 60 ml of 50 mM Tris-HCl, pH 7.5, 500 mM NaCl, 5 mM MgCl2 and 10 mM imidazole also containing one EDTAfree protease inhibitor cocktail table (Roche Diagnostics, Mannheim, Germany). Cells were then lysed by sonication using five 30s pulses on power setting 16 with 1 min pauses on ice between pulses and insoluble debris removed by centrifugation (75,600g, 20 mins, and 4 °C). Supernatant was applied to nickel agarose beads (Invitrogen) by gravity, beads were then washed twice using same lysis buffer containing 50 mM imidazole and bound proteins were eluted in 50 mM Tris-HCl, pH 7.5, 500 mM NaCl, 5 mM MgCl2 and 300 mM imidazole. For KRAS188 G12D ,KRAS188 WT and KRAS188 G12V HIS-tagged TEV protease (1.4mg/ml) was added at a ratio of 1:100 to the eluate and the sample dialysed against 50 mM Tris-HCl, pH 7.5, 500 mM NaCl, 5 mM MgCl2, overnight at 4°C. His-tagged TEV protease and cleaved HIS-tag were removed by reapplication of the digestion to nickel agarose beads (Invitrogen). Samples containing RAS protein were concentrated using Vivapore 10/20 mL concentrator (7.5 kDa molecular weight cut-off; Sartorius Vivapore). The proteins were further purified by gel filtration using a Superdex 75 Increase 10/300 GL column (GE Healthcare, Uppsala, Sweden) equilibrated with 20 mM HEPES pH 8.0, 150 mM NaCl , 5 mM MgCl2 and 1 mM DTT at a flow rate of 0.5 ml/min. Fractions corresponding to RAS were pooled and concentrated to 45-75 mg/ml for crystallization trials. Protein concentration was determined from a theoretical extinction coefficient at 280 nm calculated using ProtParam tool (https://web.expasy.org/protparam/). Protein purity was analyzed by SDS-PAGE stained with Instant Blue (Expedeon). The purification procedure of KRAS188 G12D , KRAS188 WT or KRAS188 G12V proteins were the same as for the KRAS166 G12V and KRAS169 Q61H described above, except gel filtration used the following buffer (25 mM TrisCl, pH 8.0, 100 mM NaCl, 5 mM MgCl2 and 1 mM TCEP). Nucleotide exchange for crystallographic samples was carried out following published procedures (1).
described by Luft & DeTitta (2) . Micro-crystals were suspended in 50µl reservoir solution containing the seed bead followed by mixing for 3min using a laboratory vortex. The seedstock solutions were stored at −20°C The same procedure was followed for the generation of KRAS188 G12V crystals. KRAS188 G12V and KRAS166 WT crystals were obtained in a crystallization solution of 0.1 M Tris pH 8.0, M NaOAc, 31.4% PEG 4000. Prior to data collection, crystals were cryo-protected by addition of 20% glycerol to the crystallization buffer, then flash-cooled in liquid nitrogen. For crystal soaking experiments, compounds were added individually (25-50mM of compound in 100%DMSO, with a final DMSO concentration of 6-12% v/v) to the crystallization buffer. Crystals were then transferred to solution containing compound for a minimum of 5 mins. Soaked crystals were also cryo-protected with 20% glycerol and flash-cooled in liquid nitrogen for data collection. X-ray diffraction data were collected at either Diamond Light Source (DLS, Oxfordshire, UK) or European Synchrotron Radiation Facility (ESRF, Grenoble, France). The structure of KRAS169 Q61H GPPNHP and KRAS188 G12D GPPNHP were solved by molecular replacement using Protein Data Bank (PDB) codes 3GFT and 4DSU, respectively as a search models, within the program Phaser (3). KRAS188 WT , KRAS166 G12V and KRAS188 G12V structures were again solved by molecular replacement using the KRAS188 G12D GPPNHP solved in this study as a search model. Structures were refined using REFMAC5 (4) and manually corrected using COOT (5) . The refined models were validated using MOLPROBITY (6) and Phenix software packages (7) (8) . Figures were created using PyMOL (DeLano, 2002) . Data collection and refinement statistics are shown in Supplementary Tables 1-4 .
Protein expression and purification for SPR fragment screen
The DNA sequence encoding human KRAS166 G12V (Uniprot P01116, isoform 4B, residues 1-166) was cloned into the vector pRK, modified to encode an N-terminal hexahistidine tag, TEV cleavage site and AviTag. The LMO2 and the LMO2-VH fusion cDNA were cloned into the vector pOPINS, modified to encode an N-terminal hexahistidine tag, SUMO tag and AviTag. Proteins were expressed in C41(DE3) or Lemo21 cells (NEB) using 0.5mM isopropyl 1-thio-β-D-galactopyranoside (IPTG) for overnight induction at 15ºC. Cells expressing LMO2 were supplemented with 0.1mM ZnCl2. Harvested cells were resuspended in binding buffer (50mM HEPES pH 7.5, 500mM NaCl, 5% glycerol, 10mM imidazole, 2mM 2-mercaptoethanol) supplemented with Complete Protease Inhibitors (Roche) and disrupted using a cell disruptor (Constant Systems) at 25kPSI, 5ºC. Proteins were partially purified by nickel affinity chromatography, eluting in 500mM imidazole. KRAS166 G12V protein was loaded with GppNHp as previously described (1) . The N-terminal AviTags on all proteins were biotinylated by treatment with biotin ligase enzyme (BirA) overnight at 4ºC in the presence of ATP, MgCl2 and D-biotin. The hexahistidine and SUMO tags were also cleaved from the LMO2 proteins using SUMO protease. The proteins were further purified by size-exclusion chromatography using either a HiLoad S200 16/600 column or HiLoad S75 16/600 column equilibrated in gel filtration buffer (10mM HEPES pH 7.5, 150mM NaCl, 1mM 2-mercaptoethanol) or PBS on an Akta Avant FPLC system (GE Healthcare). GST-tagged KRAS166 G12V was expressed and purified as previously described REF.
SPR screening
Biotinylated LMO2, KRAS and LMO2-VH fusion were immobilized on a streptavidin chip (GE Healthcare) and the PPI-Net library compounds were passed over the three proteins at 150μM concentration. SPR experiments were carried out using a Biacore T200 instrument (GE Healthcare) at 10 °C to preserve the protein immobilised on the sensor surface. Biotinylated proteins were immobilised on a streptavidin-coated sensor chip (chip SA, GE Healthcare). The surface was washed with 1M NaCl, 50mM NaOH before immobilising ~4000 response units (RU) of 1μM GppNHp-loaded KRAS166 G12V using the 'aim for' program. Control proteins were immobilized at RU level corresponding to an equal number of moles of protein on the sensor surface as 4000 RU of KRAS166 G12V . In practice this equated to ~4000 RU of LMO2 as the molecular weight (MW) of LMO2 is very close to KRAS166 G12V . Flow cell 1 was blocked by injecting 10mM biocytin over the surface for 5 minutes at 10μl/min and used as the reference channel. Immobilisation was carried out in HEPES running buffer (10mM HEPES pH 7.4, 150mM NaCl, 0.005% P20, 5mM MgCl2, 10µM ZnCl2). Compound solutions were prepared by transferring 1.5μl PPI-Net stock compounds at 10mM in 100% DMSO into 96-well plates (Greiner) using a multichannel pipette. 98.5μl running buffer with 3.5% DMSO was added to yield a solution of 150μM compound in running buffer with 5% DMSO. Compound solutions were injected over all 4 flow channels for 30 seconds at 30μl/min and dissociation monitored for 60 seconds. A negative control of running buffer with 5% DMSO was run after every 24 cycles. Between injections the flow system was washed with a solution of 50% DMSO. A solvent correction curve was used to correct for the effects of DMSO. Data were referenced, solvent corrected and processed using the T200 evaluation software. Single-point binding levels were exported to Excel. Data were baseline-corrected using the negative control binding levels as a reference and then binding levels measured against KRAS166 G12V plotted against binding levels measured against the control proteins. Hit compounds were tested using X-ray crystallography. PPIN-1 and PPNI-2 gave clear electron density in X-ray crystallography.
Recombinant protein expression for NMR KRAS166 G12V was cloned and isolated the same way as described in the recombinant protein expression for crystallization. KRAS166 G12V cDNA was cloned into the pGEX vector in-frame with an N-terminal Glutathione-S transferase (GST) tag. pGEX-GST-KRAS G12V was transformed into E.coli BL21 (DE3) cells. Bacterial cells were cultured at 37°C to an OD600 of 0.5 and induced with IPTG (isopropyl 1-thio-beta-D-galactopyranoside, final concentration 0.1mM) at 16°C overnight. The bacteria cultures were harvested by centrifugation and the cell pellets re-suspended in 50 mM Tris-HCl pH8.0, 140 mM NaCl, 1 mM mercaptoethanol supplemented with complete protease inhibitor (Roche). The GSTfusion proteins were purified by glutathione-sepharose column chromatography (GE Healthcare) and eluted with 50 mM Tris-HCl pH8.0, 10 mM reduced glutathione, 1 mM mercaptoethanol, 5 mM MgCl2. KRAS166 G12V protein samples were concentrated using Vivapore 10/20 mL concentrator (7.5 kDa molecular weight cut-off; Sartorius Vivapore) to a final volume of approximately 2 mL. RAS proteins were further purified by gel filtration on a HiLoad Superdex 75 10/300GL column (GE Healthcare) in a buffer containing 10 mM PBS pH 7.4, 5 mM MgCl2 at a flow rate of 0.5 mL/min. Protein concentration was determined by extinction coefficient (ε280 = 54780 M -1 cm -1 ). Protein purity was analysed by SDS-PAGE stained with Coomassie Brilliant Blue. Nucleotide exchange for crystallographic samples was carried out following published procedures (1) NMR spectroscopy NMR spectra were recorded on Bruker Avance spectrometers (AVII400 or AVIII400) in the deuterated solvent stated. The field was locked by external referencing to the relevant deuteron resonance. Chemical shifts (d) are reported in parts per million (ppm) referenced to the solvent peak. The multiplicity of each signal is indicated by: s (singlet); br. s (broad singlet); d (doublet); t (triplet); dd (doublet of doublets); tt (triplet of triplets); or m (multiplet).
The number of protons (n) for a given resonance signal is indicated by nH. Coupling constants (J) are quoted in Hz and are reported to the nearest 0.1 Hz.
WaterLOGSY experiments
WaterLOGSY experiments (9) were conducted at a 1 H frequency of 600 MHz using a Bruker Avance spectrometer equipped with a BBI probe. All experiments were conducted at 298 K. 3 mm diameter NMR tubes with a sample volume of 200 µL were used in all experiments. Solutions were buffered using an H2O PBS buffer corrected to pH 7.4 and 5mM MgCl2. The sample preparation is exemplified as follows, the compound (10 µL of a 10 nM solution in DMSO-d6) was added to an eppendorf before sequential addition of the H2O PBS buffer (163.6 µL), D2O (20 µL), and His-KRAS166 G12V -GppNHP loaded protein (6.4 µL, 311.8 µM). The resulting solution was spun to ensure full mixing and transferred to a 3 mm NMR tube before the run. For a competition experiment using Y6-ScFv VH, the preparation was carried out in a similar manner; the compound (10 µL of a 10 nM solution in DMSO-d6) was added to an eppendorf before sequential addition of the H2O PBS buffer (146.4 µL), D2O (20 µL), protein (6.4 µL, 311.8 µM) and Y6-ScFv (17.2 µL, 116.6 µM). The resulting solution was spun and transferred to a 3 mm NMR tube before the run. Negative controls (compound alone, without the protein) were prepared in a similar manner, in order to obtain an end volume of 200 µL.
FORGE Analysis
Alignments of the selected compounds were performed following the wizard menu in FORGE (http://www.cresset-group.com/forge/ (10)). Mol2 files of the Abd7 file was uploaded as the reference molecule. The protonation state for each molecule was selected by FORGE. Mol2 files for the selected molecules to be aligned were uploaded in the program (PPIN-1 and PPIN2). No other parameters were uploaded in the program until the selection for the results quality window appeared. For simplicity, no field alignments were used, only alignments from the compounds surfaces were selected from the highest score solutions to illustrate the results.
Chemical synthesis and characterization
All solvents and reagents were used as supplied (analytical or HPLC grade) without prior purification. Water was purified by an Elix® UV-10 system. Brine refers to a sat. aq. solution of sodium chloride. In vacuo refers to the use of a rotary evaporator attached to a diaphragm pump. Thin layer chromatography was performed on aluminium plates coated with 60 F254 silica. Plates were visualised using UV light (254 nm) or 1% aq. KMnO4. Flash column chromatography was performed on Kieselgel 60M silica in a glass column. NMR spectra were recorded on Bruker Avance spectrometers (AVII400, AVIII 400, AVIIIHD 600 or AVIII 700) in the deuterated solvent stated. The field was locked by external referencing to the relevant deuteron resonance. Chemical shifts (d) are reported in parts per million (ppm) referenced to the solvent peak. 1 H spectra reported to two decimal places, and 13 C spectra reported to one decimal place, and coupling constants (J) are quoted in Hz (reported to one decimal place). The multiplicity of each signal is indicated by: s (singlet); br. s (broad singlet); d (doublet); t (triplet); q (quartet); dd (doublet of doublets); td (triplet of doublets); qt (quartet of triplets); or m (multiplet). Low-resolution mass spectra were recorded on an Agilent 6120 spectrometer from solutions of MeOH. Accurate mass measurements were run on either a Bruker MicroTOF internally calibrated with polyalanine, or a Micromass GCT instrument fitted with a Scientific Glass Instruments BPX5 column (15 m x 0.25 mm) using amyl acetate as a lock mass, by the mass spectrometry department of the Chemistry Research Laboratory, University of Oxford, UK.; m/z values are reported in Daltons.
NMR spectra for the compounds are shown in Figure S6 .
General procedure A
The requisite halogen (600 mg, 2.79 mmol, 1.0 eq.), K2CO3 (1.16 g, 8.37 mmol, 3.0 eq.), the requisite boronic acid (572 mg, 3.07 mmol, 1.1 eq.), and Pd(dppf)Cl2 (100 mg, 0.140 mmol, 5 mol%) were added sequentially to a microwave vial equipped with a magnetic stirrer bar. The reaction vessel was fitted with a rubber septum and purged with N2 for 5 min, before addition of a degassed solution of 1,4-dioxane/water (5:1, 8 mL) via syringe. The vial was then sealed and the reaction heated to 100 °C for 18 h. The mixture was cooled down, diluted with EtOAc (30 mL), and washed with a 50/50 solution of water and brine (2 x 30 mL). The organic phase was dried (Na2SO4) and concentrated in vacuo. Purification by column chromatography on silica gel (solvents as stated) afforded the desired product.
General procedure B
The requisite halogen (75 mg, 0.272 mmol, 1.0 eq.), Cs2CO3 (266 mg, 0.866 mmol, 3.0 eq.), the requisite amine (53 mg, 0.354 mmol, 1.3 eq.), XPhos (13 mg, 0.027 mmol, 10 mol%) and Pd(OAc)2 (3 mg, 0.014 mmol, 5 mol%) were added sequentially to a microwave vial equipped with a magnetic stirrer bar. The reaction vessel was fitted with a rubber septum and purged with N2 for 5 min, before addition of a degassed solution of 1,4-dioxane (3 mL) via syringe. The vial was then sealed and the reaction heated to 100 °C for 24 h. The mixture was cooled down, diluted with EtOAc (30 mL), and washed with a 50/50 solution of water and brine (2 x 30 mL). The organic phase was dried (Na2SO4) and concentrated in vacuo. Purification by column chromatography on silica gel (solvents as stated) afforded the desired product.
4'-chloro-3-methoxy-1,1'-biphenyl (1)
Following General Procedure A, 3-bromoanisole (200 mg, 1.07 mmol) and 4chlorobenzylboronic acid (185 mg, 1.18 mmol) afforded the title product 1 (231 mg, 99%) as a clear oil that solidified on standing after purification on silica gel (EtOAc:pentane (1:99)). 
N-(4-((dimethylamino)methyl)phenyl)-3'-methoxy-[1,1'-biphenyl]-4-amine (Ch-1)
Following General Procedure B, A (155 mg, 0.711 mmol) and 4-amino-N,Ndimethylbenzylamine (128 mg, 0.853 mmol) afforded the title product Ch-1 (209 mg, 88%) as a yellow oil that solidified on standing after purification on silica gel (MeOH:CH2Cl2 (1:9)). 
N-(4-((dimethylamino)methyl)phenyl)-3,3'-dimethoxy-[1,1'-biphenyl]-4-amine (Ch-2)
Following General Procedure B, 2 (185 mg, 0.746 mmol) and 4-amino-N,Ndimethylbenzylamine (134 mg, 0.895 mmol) afforded the title product Ch-2 (226 mg, 91%) as a yellow oil after purification on silica gel (MeOH:CH2Cl2 (1:9)). 1 H NMR (600 MHz, MeOD) δ = 7.30 (1H, t, J 7.9) 7.29 (1H, d, J 7.9), 7.20 (2H, d, J 8.4), 7.18 (1H, d, J 2.0), 7.17 (1H, ddd, J 7.7, 1.7, 0.9), 7.14-7.12 (4H, m), 6 
4-chloro-2-fluoro-3,3'-dimethoxy-1,1'-biphenyl (3)
Following General Procedure A, 3-bromoanisole (200 mg, 1.07 mmol) and 4-chloro-2fluoro-3-methoxyphenylboronic acid (241 mg, 1.18 mmol) afforded the title product 3 (272 mg, 96%) as a yellow oil after purification on silica gel (EtOAc:pentane (1:99)). N-(4-((dimethylamino)methyl)phenyl)-2-fluoro-3,3'-dimethoxy-[1,1'- 
biphenyl]-4amine (Ch-3)
Following General Procedure B, 3 (110 mg, 0.414 mmol) and 4-amino-N,Ndimethylbenzylamine (75 mg, 0.497 mmol) afforded the title product Ch-3 (226 mg, 91%) as a yellow oil after purification on silica gel (MeOH:CH2Cl2 (1:9)). Tissue culture HEK293T and DLD-1 cells and were grown in DMEM, high glucose, GlutaMaxÔ medium (Life Technologies) supplemented with 10% FBS (Sigma) and 1% Penicillin/Streptomycin (Life Technologies). Cells were grown at 37°C with 5% CO2. The KRAS genotype in DLD-1 cells (heterozygous for KRAS G13D /KRAS wild type) was confirmed by RNA analysis and sequencing (11) .
BRET bioassay
The BRET-based RAS biosensors are built by fusing a donor molecule, a variant of the Renilla Luciferase (RLuc8), to full-length mutant RAS (KRAS G12A , KRAS G12C , KRAS G12D , KRAS G12V , KRAS G12R , NRAS Q61H and HRAS G12V mutants) and an acceptor molecule, GFP 2 , to RAS binders (iDAb RAS) or RAS effectors (full-length CRAF; PI3Ka, PI3Kg, CRAF RBDs and RALGDS RA) (11) . A BRET signal (or BRET ratio) occurs only when the donor (e.g. RLuc8-KRAS G12D ) and acceptor (e.g. GFP 2 -CRAF FL ) molecules are in close proximity (≤ 10 nm). A competition assay involves the addition of a competitor (i.e. anti-RAS compounds) and is used to determine whether an inhibitor can interfere with RAS proteinprotein interactions (PPIs). If the compounds impede RAS PPIs, a BRET signal decreased is monitored; otherwise the BRET signal is unchanged. The BRET assay was performed as described in detail elsewhere (11) . Briefly, 650,000 HEK293T cells were transfected with donor plasmid (RLuc8-mutant RAS) and acceptor plasmids (fusions of RAS binders/effectors with GFP 2 ) to allow the assessment of inhibitors of RAS-effector interaction. The transfection was carried out using Lipofectamine 2000 transfection reagent (Thermo-Fisher). Cells were detached 24 hours later and washed with PBS and seeded in a white 96 well plate (clear bottom, PerkinElmer, cat#6005181) in OptiMEM no phenol red medium (Life Technologies) supplemented with 4% FBS. Cells were left for 4 hours at 37 °C before adding compounds. 10 mM stock compounds in 100% DMSO were diluted in OptiMEM no red phenol + 4% FBS to reach 10X the final concentration (2% DMSO for each concentration). The final concentrations in the cells were 0, 5, 10 and 20 µM (with final 0.2% DMSO each). Quadruplicates were performed for each point. Cells were left for an additional 20 hours at 37 °C before the BRET2 signal reading directly after addition of Coelenterazine 400a substrate (10 µM final) to cells (Cayman Chemicals, cat#16157). BRET2 reading was done on an Envision instrument (2103 Multilabel Reader, PerkinElmer) with the BRET2 Dual Emission optical module (515 nm ± 30 and 410 nm ± 80; PerkinElmer) or with a CLARIOstar instrument. The BRET ratio corresponds to the light emitted by the GFP 2 acceptor constructs (515 nm ± 30) upon addition of Coelenterazine 400a divided by the light emitted by the RLuc8 donor constructs (410 nm ± 80) with subtraction of the background (same ratio but with RLuc8 construct alone transfected in cells). The normalized BRET ratio is the BRET ratio normalized to the DMSO negative control and calculated as follows: (BRETcompound / BRETDMSO) x 100, where BRETcompound correspond to the BRET ratio for the compoundtreated cells, BRETDMSO to the DMSO-treated cells. Each experiment was repeated at least twice.
Quantification and statistical analysis
Statistical analyses of the BRET assays were performed using a one-way ANOVA followed by Dunnett's post-tests (*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001) using GraphPad Prism 7 software.
Biomarker Western blot assay
DLD-1 cells were seeded at 4.5 x 10 5 cells per well in 6-well plates and incubated overnight. The media was aspirated and the cells were washed twice with PBS, before 2ml of serum free DMEM was added to the cells, which were incubated for a further 24 hours. The following day the media was replaced with compound containing media (0-20uM compound, with 0.2% DMSO) and the cells were incubated under culture conditions for 2.5 hours. The cells were stimulated with 50 ng/ml EGF for 10 min at 37°C. The cells were washed with cold PBS and were lysed using RIPA buffer (50mM Tris, pH 8.0, 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS) containing 1 mM DTT, CompleteÔ EDTA-free protease inhibitor and PhosSTOPÔ (Roche). Cell lysates were sonicated using a BioruptorÒ Pico Sonication System (Diagenode) and the protein concentration of each sample was quantified using the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific). 10ug of protein was electrophoresed on a 12% Bis-Tris gel and bands were subsequently transferred to a AmershamÔ HybondÒ P 0.45 µm PVDF membranes (GE Healthcare). The membranes were blocked with 10%-BSA-TBST or 5%milk-TBST before being incubated overnight at 4°C with appropriate antibodies (antiphospho-p44/22 MAPK (ERK1/2) (1/5000, CST, 9101S), anti-p44/42 MAPK (total ERK1/2) (1/1000, CST, 9102S), anti-phospho-AKT S473 (1/2000, CST, 4058S), anti-AKT (1/2000, CST, 9272S), anti-cyclophilin B (1/1000, Abcam, 178397) ). The membranes were washed with TBST and incubated with anti-rabbit IgG HRP-linked (1/2500, CST, 7074S) secondary antibody for 2 hours at room temperature. Following thorough washing the membranes were developed using PierceÔ ECL Western Blotting Substrate (Thermo Fisher Scientific) and CL-XPosureÔ films (Thermo Fisher Scientific).
Suplementary Figures Figure S1. Comparison of potential compound-binding pockets in RAS proteins (wild type and mutant forms)
The structural data for the different RAS proteins and different length proteins has been analyzed to assess potential binding pockets. Four possible pockets exist in full length RAS proteins (Panel A). Pocket I is a hydrophobic pocket near the switch regions; pocket II is a shallow pocket; pocket III is the nucleotide binding pocket and pocket IV is found at the carboxy terminus Figure S3 . Comparison of the structures of the mutant forms of KRAS188 G12D and KRAS188 G12V The structures of KRAS188 G12D and KRAS188 G12V (isoform 4B) are compared in the switch regions with bound GTP-analogue GppNHp. PANEL A. KRAS188 G12D ribbon representation, with Switch I and II in orange, illustrating the interactions of a second Mg ion with G60 found in switch II which stabilize the switch II region. Mg are shown as large magenta spheres. PANEL B. KRAS188 G12V ribbon representation for the switch II region (in green). No second Mg ion was identified in these crystals consistent with an increase in the flexibility of the switch II region of the protein. PANEL C. Ribbon diagram of an alignment of the KRAS188 G12D and G12V. The difference between these structures is the flexibility of the switch II region. KRAS188 G12D (switch II shown in orange) has a stable switch II due to the presence of an extra Mg, KRAS188 G12V (switch shown in green) has an unstable switch II because of the lack of a second Mg ion around that region. PANEL D. Ribbon diagram of an alignment of the wild type KRAS188 and KRAS188 G12D . There are no clear differences between these structures, both contain two Mg atoms that gives a higher degree of stability to the switch II regions and the folding is almost identical. 
Relative pERK/ERK Ratio
Western blot data were obtained as described in Figure 5 . Data were obtained from three independent experiments (biological replicates) and error bars are shown for standard deviations. Images were scanned and quantified using ImageJ software, and the relative quantity of phosphorylated protein was calculated with reference to unphosphorylated protein (eg. pAKT/AKT). The ratios were normalised against the data for DMSO-only control levels. 
